ADDICTOLYON
Services Hospitalo-Universitaires d'Addictologie de Lyon
GALLERY
Principales Publications Scientifiques depuis 2018
—
de Ternay J, Leblanc P, Michel P, Benyamina A, Naassila M, Rolland B.
One-month alcohol abstinence national campaigns: a scoping review of the harm reduction benefits.
Harm Reduct J. 2022 Mar 4;19(1):24. doi: 10.1186/s12954-022-00603-x
Chapron SA, Nourredine M, Dondé C, Haesebaert F, Micoulaud-Franchi JA, Geoffroy PA, Rolland B. Efficacy and safety of topiramate for reducing impulsivity: A transdiagnostic systematic review and meta-analysis of a common clinical use. Fundam Clin Pharmacol. 2021 Jul 1.doi: 10.1111/fcp.12710.
Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, Hjelmström P, Nubukpo P, Brousse G, Rolland B. Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder. Patient Prefer Adherenc. 2021 Jun 14;15:1259-1267.
Nourredine M, Gering A, Fourneret P, Rolland B, Falissard B, Cucherat M, Geoffray MM, Jurek L..
Association of Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence With the Risk of Subsequent Psychotic Disorder: A Systematic Review and Meta-analysis.
JAMA Psychiatry. 2021 May 1;78(5):519-529
Luquiens A, Berger-Viergat A, Larrieu A, Artigaud L, Fener C, Adamson S, Laprévote V, Rolland B.
Validation of the French version of the Cannabis Use Disorder Identification Test-Revised and comparison with the Cannabis Abuse Screening Test for screening cannabis use disorder in a psychiatric sample.
Drug Alcohol Rev. 2021; doi: 10.1111/dar.13298
Laconi S, Palma-Álvarez RF, Stöver H, Padbgerg C, Jamin D, Meroueh F, Chappuy M, Roncero C, Rolland B.
Validation of the Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales in French, Spanish, and German languages, among a sample of opioid users.
Eur Addict Res 2021; in Press
Rolland B, Trojak B, Nourredine M, Bachellier J, Chappuy M, Bendimerad P, Kosim M, Hjelmström P, Meroueh F, Nubukpo P, Brousse G.
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Drug Alcohol Depend. 2021; 220:108492.
Carton L, Nourredine M, Rolland B.
Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN)
Therapies 2021; https://doi.org/10.1016/j.therap.2020.12.009
Bertin C, Delage N, Rolland B, Pennel L, Fatseas M, Trouvin AP, Delorme J, Chenaf C, Authier N.
Analgesic opioid use disorder in patients with chronic non-cancer pain: A holistic approach for tailored management
Neurosci Biobehav Rev. 2021; 121:160-174.
Fourneret P, Zimmer L, Rolland B.
How to improve in France ADHD transition support from childhood to adulthood
Encephale. 2020; S0013-7006(20)30238-4.
Pabst A, Peyroux E, Rolland B, de Timary P, Maurage P
Hostile attributional bias in severe alcohol use disorder
J Psychiatr Res. 2020; 129:176-180.
Dondé C, Brunelin J, Mondino M, Cellard C, Rolland B, Haesebaert F.
The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review
Neurosci Biobehav Rev. 2020; 118:121-133.
Rolland B, Haesebaert F, Zante E, Benyamina A, Haesebaert J, Franck N.
Global changes and factors of increase in caloric/salty food, screen, and substance use, during the early COVID-19 containment phase in France: a general population online survey
JMIR Public Health Surveill. 2020; doi: 10.2196/19630.
Chappuy M, Trojak B, Nubukpo P, Bachellier J, Bendimerad P, Brousse G, Rolland B.
Prolonged-release buprenorphine formulations: perspectives for clinical practice
Therapies. 2020; https://doi.org/10.1016/j.therap.2020.05.007
Gelis A, Cervello S, Rey R, Llorca G, Lambert P, Franck N, Dupeyron A, Delpont M, Rolland B.
Peer Role-Play for Training Communication Skills in Medical Students: A Systematic Review.
Simul Healthc. 2020; doi: 10.1097/SIH.0000000000000412
Geoffroy PA, Lejoyeux M, Rolland B.
Management of insomnia in alcohol use disorder.
Expert Opin Pharmacother. 2020; 21(3):297-306. doi: 10.1080/14656566.2019.1705279.
Chappuy M, Boulanger A, Nourredine M, Fourneret P, Rolland B.
Disparate regulatory status of methylphenidate for adults with ADHD across Europe.
Lancet Psychiatry. 2020; 7(1):e1-e2. doi: 10.1016/S2215-0366(19)30482-1.
Meyrel M, Rolland B, Geoffroy PA.
Alterations in circadian rhythms following alcohol use: A systematic review.
Prog Neuropsychopharmacol Biol Psychiatry. 2020; 99:109831. doi: 10.1016/j.pnpbp.2019.109831.
Rolland B, Simon N, Franchitto N, Aubin HJ.
France Grants an Approval to Baclofen for Alcohol Dependence.
Alcohol Alcohol. 2020; 55(1):44-45. doi: 10.1093/alcalc/agz082.
Pignon B, Sescousse G, Amad A, ..., Roelandt JL, Rolland B.
Alcohol Use Disorder Is Differently Associated With Psychotic Symptoms According To Underlying Psychiatric Disorders: A General Population Study.
Alcohol Alcohol. 2020; 55(1):112-120. doi: 10.1093/alcalc/agz077
Barre T, Marcellin F, Di Beo V, ..., Bailly F, Coste M, Authier N, Carrieri MP, Rolland B.
Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
Li Y, Wang Z, Boileau I, Dreher JC, ..., van Timmeren T, Sescousse G.
Altered orbitofrontal sulcogyral patterns in gambling disorder: a multicenter study.
Transl Psychiatry. 2019; 9(1):186. doi: 10.1038/s41398-019-0520-8
Vorspan F, Hjelmström P, Simon N, ..., Kosim M, Rolland B.
What place for prolonged-release buprenorphine depot formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
Expert Opin Drug Deliv. 2019. 16(9):907-914. doi: 10.1080/17425247.2019.1649252.
Carton L, Auger F, Kyheng M, ..., Bordet R, Rolland B.
Dose-dependent metabolite changes after ethanol intoxication in rat prefrontal cortex using in vivo magnetic resonance spectroscopy.
Sci Rep. 2019; 9(1):10682. doi: 10.1038/s41598-019-47187-4.
De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, Maurage P, Cottencin O, Carrieri PM, Rolland B.
Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain.
Front Pharmacol. 2019; 10:627. doi: 10.3389/fphar.2019.00627.
Mas-Herrero E, Sescousse G, Cools R, Marco-Pallarés J.
The contribution of striatal pseudo-reward prediction errors to value-based decision-making.
Neuroimage. 2019; 193:67-74.doi: 10.1016/j.neuroimage.2019.02.052.
Groefsema MM, Engels RCME, Voon V, Schellekens AFA, Luijten M, Sescousse G.
Brain responses to anticipating and receiving beer: Comparing light, at-risk, and dependent alcohol users.
Addict Biol. 2019; e12766. doi: 10.1111/adb.12766.
Rojas Rojas T, Di Beo V, ..., Bailly F, Coste M, Authier N, Carrieri MP, Rolland B, Marcellin F.
Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project.
Int J Drug Policy. 2019; 72:61-68. doi: 10.1016/j.drugpo.2019.05.013.
Rolland B, Dricot L, Creupelandt C, Maurage P, De Timary P.
Respective influence of current alcohol consumption and duration of heavy drinking on brain morphological alterations in alcohol use disorder.
Rolland B, D'Hondt F, Montègue S, Brion M, Peyron E, D'Aviau de Ternay J, de Timary P, Nourredine M, Maurage P.
Neuropsychol Rev. 2019; 29(1):103-115. doi: 10.1007/s11065-018-9395-3
Lenglard F, Berger-Vergiat A, Ragonnet D, Duvernay N, Lack P, Poulet E, Zoulim F, Chappuy M.
Thérapie. 2019; 74(4):477-486.
Agabio R, Sinclair JM, Addolorato G, ..., Rolland B, Stafford A, Thompson A, van den Brink W, de Beaurepaire R, Leggio L.
Baclofen for the treatment of alcohol use disorder: the Cagliari Statement.
Lancet Psychiatry. 2018; 5(12):957-960.
D'Hondt F, Lescut C, Maurage P, ..., Montègue S, Jardri R, Rolland B.
Psychiatric comorbidities associated with a positive screening using the Montreal Cognitive Assessment (MoCA) test in subjects with severe alcohol use disorder.
Drug Alcohol Depend. 2018; 191:266-269.
Simon N, Moirand R, Dematteis M, Bordet R, Deplanque D, Rolland B.
Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder.
Front Psychiatry. 2018; 9:385.
Rolland B, Simon N, Franchitto N.
Safety Challenges of Using High Dose Baclofen for Alcohol Use Disorder: A Focused Review.
Front Psychiatry. 2018; 9:367.
Carton L, Pignon B, Baguet A, ..., Geoffroy PA, Rolland B.
Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study.
Drug Alcohol Depend. 2018; 187:40-47.